Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

High Roller Technologies gets NFA license to launch U.S. prediction markets via Crypto.com FCM.

Market News
26 Jun 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

High Roller Technologies' subsidiary, ROLR US LLC, has been approved as a member of the National Futures Association and registered as a guaranteed introducing broker under Crypto.com FCM's guarantee. This regulatory milestone enables High Roller to launch its ROLR prediction markets platform in the U.S., offering customers access to event contracts in sports, finance, and entertainment. Crypto.com FCM will handle customer accounts and regulatory infrastructure, while High Roller focuses on user experience and brand growth. The launch is pending final technology integration and testing.

More News

Life Sciences Virtual Investor Forum presentations now available on-demand for 90 days

Life Sciences Virtual Investor Forum presentations now available on-demand for 90 days

Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now accessible on-demand for 90 days. This event featured multiple life sciences companies presenting to investors, with opportunit...

Others
Neutral
1 hour ago
Vaxart urges shareholders to vote for all six director nominees to secure biotech growth and funding.

Vaxart urges shareholders to vote for all six director nominees to secure biotech growth and funding.

Vaxart, a clinical-stage biotech company, has published a presentation urging shareholders to vote for all six of its director nominees at the upcoming Annual Meeting. The company highlights its progress in developing oral vaccines for COVID-19, noro...

Company Fundamentals
Bullish
1 hour ago
Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.

Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.

Axsome Therapeutics has initiated the FOCUS-3 Phase 3 clinical trial to evaluate solriamfetol as a treatment for adolescents aged 12 to under 18 with ADHD. This randomized, double-blind, placebo-controlled study will enroll about 468 patients to asse...

Market News
Bullish
2 hours ago
Complex small molecules reshape drug R&D, demanding integrated discovery to manufacturing solutions.

Complex small molecules reshape drug R&D, demanding integrated discovery to manufacturing solutions.

WuXi AppTec highlights how the increasing structural complexity of small molecules, such as targeted protein degraders and covalent inhibitors, is transforming drug research and development. These new molecules require advanced, integrated approaches...

Market News
Bullish
2 hours ago
Fury Gold Mines elects six directors, appoints auditor, and renews long-term incentive plan at AGM.

Fury Gold Mines elects six directors, appoints auditor, and renews long-term incentive plan at AGM.

At its Annual General Meeting on June 25, 2026, Fury Gold Mines shareholders approved fixing the board size at six directors and elected all nominated directors. PricewaterhouseCoopers LLP was appointed as the company's auditor. Shareholders also ren...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App